Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.06
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-572206.00 · quality 76.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$516568
P/E
N/A
•EV/EBITDA
N/A
•ROE
27.9%
↑Gross Margin
93.2%
↑Debt/Equity
-0.52
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-31.2%
FCF CAGR
—
FCF margin
-1197.8%
FCF / Net income
0.45x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $47771.0 · net income $-1.3M · FCF $-572206.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $47771.00 | $47771.00 | $82963.00 | $102854.00 | $146812.00 |
| Net Income | $-1.3M | $-1.3M | $-1.1M | $-1.6M | $-1.4M |
| EBITDA | $-1.1M | $-1.1M | $-946881.00 | $-1.6M | $-1.4M |
| EPS | -0.13 | -0.13 | -0.11 | -0.17 | -0.37 |
| Gross Margin | 93.2% | 93.2% | 77.0% | 78.4% | 79.0% |
| Operating Margin | -2202.9% | -2202.9% | -1147.7% | -1526.0% | -986.9% |
| Net Margin | -2648.8% | -2648.8% | -1299.6% | -1580.1% | -932.6% |
| Balance Sheet | |||||
| Debt/Equity | -0.52 | -0.52 | -0.47 | -0.50 | -0.58 |
| Current Ratio | 0.01 | 0.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-572206.00 | $-572206.00 | $-496547.00 | $-1.0M | $-1.5M |
| Returns | |||||
| ROE | 27.9% | 27.9% | 33.0% | 74.4% | 244.7% |
| Growth & Yield | |||||
| Revenue Growth | -42.4% | -42.4% | -19.3% | -29.9% | — |
| EPS Growth | -18.2% | -18.2% | 35.3% | 54.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+450.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.11 → -0.13
Residual
+450.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.